EMA registers nerve disorder as AZ shot side-effect
The European Medicines Agency added on Wednesday Guillain-Barré syndrome, a rare nerve-damaging disorder to the list of possible side-effects of AstraZeneca’s COVID-19 vaccine.
Europe’s medicines regulator cited “at least a reasonable possibility” of the syndrome following reports of 833 GBS cases worldwide out of the nearly 592 million administered doses. The side-effect was given the lowest frequency level and marked as “very rare”.
The EMA stressed that the benefits of receiving the coronavirus shot still outweigh the risks. Meanwhile, the US drug agency has also found GBS to be a side-effect in the Johnson&Johnson COVID-19 jab.
Get involved!
Comments